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PI3K/AKT/PTEN pathway is important in the regulation of angiogenesis mediated by vascular endothelial growth factor in many
tumors including leukemia. The signaling pathway is activated in leukemia patients as well as leukemia cell lines together with
a decrease in the expression of PTEN gene. The mechanism by which the signaling pathway regulates angiogenesis remains to
be further elucidated. However, it has become an attractive target for drug therapy against leukemia, because angiogenesis is a
key process in malignant cell growth. In this paper, we will focus on the roles and mechanisms of PI3K/AKT/PTEN pathway in
regulating angiogenesis.
1.Introduction
Angiogenesis is the process by which new blood capillaries
are generated from the preexisting blood vessels [1, 2].
Tumor angiogenesis is essential for tumor growth, invasion,
and metastasis [3, 4]. This process can be triggered by
a series of signal pathways including extracellular signals
such as growth factors (Figure 1). It is a complex process
that is also regulated by pro- and antiangiogenic factors.
In other words, the angiogenesis and vasculature are regu-
lated through the change of balance between the collective
actions of proangiogenic factors such as vascular endothelial
growth factor (VEGF) and angiogenic inhibitors such as
thrombospondin-1(TSP-1). These factors can be derived
from diﬀerent sources such as stromal cells, extracellular
matrix, and cancer cells. Their relative contribution is likely
to be diﬀerent according to the diﬀerence in tumor types.
The interaction btween cancer cells and vascular endothelial
cells in the tumor microenvironment aﬀectsthe angiogenesis
[5,6].Leukemiaisanaggressivemalignancycharacterizedby
the accumulation of immature leukemia blasts in the bone
marrow. Bone marrow angiogenesis is therefore important
for both leukemogenesis, and the leukemic bone marrow
shows increased microvascular density [7].
VEGF and VEGF receptor (VEGFR) are major angiogen-
esisinducerassociatedwithtumorangiogenesisinnumerous
solid or hematological malignancies. VEGF binds to VEGF
receptor, which leads to the activation of phosphatidylinos-
itol 3-kinase (PI3K)/Akt signaling pathway. In addition to
the PI3K/Akt signaling, phosphatase and tensin homolog
deleted on chromosome 10 (PTEN) play an important
role as a molecular inhibitor of PI3K/Akt signaling in
multiple cellular functions such as cell proliferation, cell-
cycle progression, and survival [8]. PI3K/Akt signaling
regulates angiogenesis through aﬀecting the expression of
VEGF (Figure 1). It may contribute to tumor angiogenesis
not only via the autocrine pathway to tumor cells but also
via a paracrine pathway to the surrounding microvessels.
The ampliﬁcation and mutations of PI3K/Akt and the loss
of the tumor suppressor PTEN are common in various
kinds of human tumors including leukemia. In addition, the
activation of PI3K/Akt signaling is commonly observed in
numerous leukemia patients and leukemia cell lines together
with a decrease in the expression of PTEN [9]. As siRNA2 Advances in Hematology
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Figure 1: Schematic representation of PI3K/AKT/PTEN signaling. Examples of molecules known to act on angiogenesis via PI3K/AKT
regulatory pathways are shown.
against PI3K and Akt greatly decreases tumor growth and
angiogenesis [10], it is considered that PI3K/Akt pathways
indeed involved in the tumor angiogenesis. In this paper,
we will focus on the roles and mechanisms of PI3K, AKT,
and PTEN in regulating angiogenesis and roles of the
downstream targets for transmitting the signals.
2. Function of PI3K/AKT in Angiogenesis
The active form of PI3K is an oncogene, and ampliﬁcations
and mutations of PI3K are commonly found in many kinds
of human cancers [11]. Genetic alterations of PI3K lead to
dysfunction of vasculature and angiogenesis. In addition,
forced expression of PI3K alone is suﬃcient to increase
angiogenesis via increased VEGF expression [12]. The PI3K
in mammalian cells forms a family that can be divided
into three classes based on their structure, distribution, and
mechanismofactivation(Figure 2).ClassIPI3Ksaredivided
into class IA and class IB based on diﬀerent associated
adaptors. Class IA PI3Ks are activated by receptor tyrosine
kinases, while class IB PI3Ks are activated by G-protein-
coupled receptors. These PI3Ks are heterodimers consisting
of a regulatory subunit such as p85 and a catalytic subunit
such as p110. The p110 is required to control endothelial cell
migration and angiogenesis, and p110-knockout endothelial
cells lead to embryonic lethality with severe defects in
angiogenic sprouting and vascular remodeling [13]. The
phospholipid second messengers generated by PI3K provide
a common mechanism for multiple steps during angio-
genesis. PI3K inhibitor LY294002 decreased tumor-induced
angiogenic response [14].
Serine-threonine protein kinase AKT (also known as
protein kinase B) is a major downstream target of PI3K for
regulating tumor growth and angiogenesis. AKT is initially
found to be the cellular homolog of AKT8 retroviral
oncogene [15]. Human AKT has three isoforms: AKT1,
AKT2, and AKT3. PIP3, a product of PI3K, binds to AKT
and leads to the membrane recruitment of AKT and also
binds to phosphoinositide-dependent kinase 1 (PDK1) via
their pleckstrin homology (PH) domains, and then PDK1
phosphorylates AKT in the kinase domain (Thr 308 in
AKT1). For the full activation of AKT, the phosphorylation
within the carboxyl-terminal regulatory domain (Ser 473 in
AKT1)ofAKTbyPDK2isrequired[16].Schematicstructure
of the predicted AKT1 protein is shown in Figure 3(a).O n c e
activated, AKT moves to the cytoplasm and nucleus, where
it phosphorylates, activates, or inhibits many downstream
targets to regulate various cellular functions including
angiogenesis. The forced expression of active forms of
PI3K/Aktincreasesthenumberofsproutingvesselstoinduce
angiogenesis. Bone-marrow-derived endothelial cells and
some hematopoietic progenitors participate in the angiogen-
esis. AKT can activate NF-κBp a t h w a y[ 17], performing a
complicated network in regulating angiogenesis (Figure 1).
Transgenic expression of Myr-AKT in endothelial cells is
suﬃcient to form the structural and functional features of
blood vessels [18]. The sustained endothelial AKT activation
causes enlarged blood vessels and its eﬀect can be reversed
by the AKT inhibition. AKT inhibits the GTPase-activating
protein (GAP) activity of the tuberous sclerosis complex 1
(TSC1)andTSC2complexbyphosphorylatingTSC2tuberin
protein, leading to the accumulation and activation of the
mTOR and raptor complex [19]. The mTOR mediates the
phosphorylation of the ribosomal protein S6 kinases and
eukaryotic translation initiation factor 4E-binding protein 1
leadingtothereleaseofthetranslationinitiationfactoreIF4E
[20].
3. Function of PTEN inAngiogenesis
PTEN is a dual-speciﬁcity phosphatase which has protein
phosphatase activity and lipid phosphatase activity thatAdvances in Hematology 3
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antagonizes PI3K activity [21]. PTEN gene, which encodes
403-residueaminoacids,islocatedonchromosome10q23.3.
Schematic structure of the predicted PTEN protein is
shown in Figure 3(b). PTEN negatively regulates the activity
of PI3K/Akt signaling through converting phosphatidyli-
nositol 3,4,5-triphosphate (PIP3) into phosphatidylinositol
4,5-bisphosphate (PIP2). Because PTEN protein plays an
important role in regulating proliferation and invasion of
manycancercells,PTENisconsideredasatumorsuppressor.
PTEN also modulates angiogenesis via down-regulating
PI3K/Akt pathway in many tumors including leukemia
[22–24]. Although the eﬀects of PTEN on invasion of
hematopoietic cells and its clinical signiﬁcance remain to
be further elucidated, PTEN would be a candidate target
to be addressed for inhibiting angiogenesis along with the
treatment of leukemia [25]. Recent study has demonstrated
that in addition to suppressing AKT activation, PTEN also
controls the activity of Jun N-terminal kinase (JNK) [26].
PTEN-knockout endothelial cells cause embryonic lethality
due to endothelial cell hyperproliferation and impaired
vascular remodeling, whereas PTEN+/− endothelial cells
enhance neovascularization and tumor angiogenesis to
increase tumor growth [27]. As PTEN is frequently mutated
or lost in a number of human cancers, PTEN can be
upregulated by early-growth-regulated transcription factor
1 (EGR1) through direct binding to the PTEN promoter
[28]. In addition, peroxisome-proliferator-activated receptor
γ (PPARγ), p53, and activating transcription factor 2
(ATF2) can also transcriptionally upregulate PTEN [29,
30], while transforming growth factor (TGF)-β,n u c l e a r
factor kappaB (NF-κB), and Jun negatively regulate PTEN
expression [31, 32]. Interestingly, rosemary extract represses
PTEN expression in K562 leukemic culture cells [33]. Some
microRNAs such as miR-21, miR-19a, and miR-214 inhibit
PTENthroughtargetingthe3 -untranslatedregionofPTEN,
leadingtoinhibitionofPTENtranslation[34].PTENactivity
can also be regulated by the posttranslational regulation
including phosphorylation, acetylation, and oxidation.4 Advances in Hematology
4.DownstreamMoleculesMediatedby
PI3K/AKT/PTEN inRegulating Angiogenesis
PI3K/Akt signaling pathway induces tumor growth through
the expression of angiogenic factors and the inhibition
of antiangiogenic molecules. PI3K/Akt and their eﬀectors,
hypoxia-inducible factor-1α (HIF-1α) and VEGF, play key
roles in regulating the angiogenesis [35, 36]. PI3K/Akt may
also regulate angiogenesis by several downstream targets
such as mTOR/p70S6K1, FOXO, NOS, and GSK-3β. These
t a r g e t sc o m m o n l yu p r e g u l a t eH I F - 1 α expression which
induces VEGF transcriptional activation. Inhibition of GSK-
3β can upregulate HIF-1α expression and increase β-catenin
activity [37]. Hypoxia induces HIF-1α production through
the increase of its stability and induces VEGF expression
in a HIF-1-dependent manner. PI3K can also induce VEGF
expression through HIF-1α and NF-κB activation. PI3K/Akt
cansuppressTSP1,theendogenousantiangiogenicmolecule,
in both cancer cells and endothelial cells [38]. The TSP1
is a family member of TSP proteins with potent antian-
giogenic activity. TSP1 inhibits angiogenesis endothelial
cell proliferation and migration. In contrast, TSP1 is an
important autocrine factor for vascular smooth muscle cell
proliferation and migration. AKT1-knockout mice showed
impaired vascular maturation with decreased expression of
TSP-1 and TSP-2, while reexpression of TSP-1 and TSP-2 in
mice transplanted with wild-type bone marrow is associated
with the angiogenesis [39]. The endothelial NOS (eNOS)
is critical for VEGF-triggered postnatal angiogenesis [40,
41]. Several protein kinases, such as Akt, AMP-activated
protein kinase (AMPK), and protein kinase A (PKA), are
known to activate eNOS [42]. Among them, Akt has
e m e r g e da sac e n t r a lr e g u l a t o rf o re N O Sa c t i v a t i o nb y
VEGF.InhibitionofAktactivityimpairsthephosphorylation
of the human homologue of murine double minute-2
(HDM2), resulting in the destabilization of HDM2 [43]. It
is known that Akt-dependent phosphorylation of HDM2
causes nuclear translocation of HDM2 followed by HDM2-
mediated inactivation of p53. Overexpression of p70S6K1
in microvascular endothelial cells enhanced tumor growth
andangiogenesis,whileHIF-1αsiRNAsigniﬁcantlyinhibited
tumor growth and angiogenesis, suggesting that endothelial
p70S6K1 controls tumor angiogenesis through HIF-1α [44].
5.InhibitorsInvolvedinPI3K/AKT Signaling
Pan-PI3K inhibitors were initially discovered; however, iso-
form-speciﬁc PI3K inhibitors have less toxicity to the cells
than pan-PI3K inhibitors, which could be used to speciﬁcally
target PI3K activation in certain cancer cells. Pan-PI3K
inhibitors, wortmannin and LY294002, are commonly used
to inhibit cancer cell proliferation and tumor growth [45].
Wortmannin is a fungal product, which exerts its eﬀect
by the covalent interaction to the conserved Lys802 of the
p110α catalytic subunit. Both wortmannin and LY294002
also cross-react with PI3K-related kinases such as mTOR
and DNA-dependent protein kinases. These inhibitors have
poor solubility and high toxicity because they target a
broad range of PI3K-related enzymes. A novel pegylated
17-hydroxywortmannin (PWT-458) is watersoluble and has
shown improvements in drug stability [46]. A p110δ-speciﬁc
inhibitor (IC486068) enhances radiation-induced tumor
vascular destruction [47].
The ﬁrst developed group of AKT inhibitors was lipid-
basedinhibitorsthatincludeperifosine,phosphatidylinositol
ether lipid analogs (PIAs), and D-3-deoxy-phosphatidyl-
myoinositol-1-[(R)-2-methoxy-3-octadecyloxyropyl hydro-
gen phosphate] (PX-316), which showed antitumor eﬀects.
Perifosine inhibits the translocation of AKT to the cell
membrane [48]. Inositol (1,3,4,5,6) pentakisphosphate [Ins
(1,3,4,5,6) P5], one of the PI3K/AKT inhibitors, also inhibits
tumor growth and angiogenesis [49]. Several other AKT
antagonistssuchas9-methoxy-2-methylellipticiniumacetate
(API-59-OMe), indazole-pyridine A-443654, and isoform-
speciﬁc canthine alkaloid analogs have been identiﬁed and
shown to inhibit cancer cell growth and induce apopto-
sis. Other kinds of AKT inhibitors include peptide-based
inhibitorsofAKT,pseudopeptidesubstratesofAKT,asingle-
chain antibody against AKT, an inhibitory form of AKT
mutant, and siRNA, against AKT.
The mTOR inhibitors such as rapamycin and its analogs
inhibit mTOR activation by binding to FK506-binding pro-
tein-12 (FKBP12) [50] .T h e r ei saf e e d b a c kl o o pb e c a u s e
p70S6K1 negatively regulates insulin receptor substrate and
PDGF receptor. Rapamycin or its analogs can activate
upstream molecules including AKT due to the loss of
feedback inhibition. It is important to exploit the potential
beneﬁts of the targeted therapies and optimal treatment with
these inhibitors.
6.Perspective
The bone marrow of the leukemia patients has increased
blood vessel content compared to normal counterparts,
suggesting that leukemia progression might be accompa-
nied with an increase of vascularization and suggesting
the possibility for a role of antiangiogenic therapy in
the treatment of leukemia. PI3K/Akt/PTEN signaling reg-
ulates angiogenesis through the interaction of cancer cells
and tumor microenvironments including endothelial cells.
Angiogenesis inducers such as VEGF can activate PI3K/Akt
signaling for inducing angiogenesis. Given the important
role of the signaling pathway in regulating tumor growth
and angiogenesis, development of therapeutic drugs using
the PI3K/Akt signaling inhibitors becomes important for
cancer treatment. In addition, improving the function of
PTEN oﬀers another approach for targeting angiogenesis
and apoptosis induction, which could be important for
the development of leukemia therapeutics [51]. PI3K/Akt
in turn regulates tumor growth and angiogenesis through
downstream targets, mTOR, p70S6K1, HIF-1, and VEGF.
Their upstream and downstream molecules are commonly
altered in human cancers and play an important role
in angiogenesis. Accordingly, PI3K/Akt pathway inhibitors
a r el i k e l ym o r ee ﬀective in patients with active PI3K/Akt
signaling in case such as PTEN mutations. The therapeuticAdvances in Hematology 5
methodstargetingPI3K/Akt/PTENpathwaywouldrepresent
the promising leukemia therapy in the future.
Conﬂict of Interests
The authors declare that they have no ﬁnancial conﬂict of
interests.
Acknowledgments
This work was supported by grants-in-aid from the Ministry
of Education, Culture, Sports, Science and Technology in
Japan and Nara Women’s University Intramural Grant for
Project Research. In addition, this work was supported in
part by the grant from the Fuji Foundation for Protein
Research.
References
[1] S. Piyaviriyakul, K. Shimizu, T. Asakawa, T. Kan, P. Siripong,
and N. Oku, “Anti-angiogenic activity and intracellular dis-
tribution of epigallocatechin-3-gallate analogs,” Biological and
Pharmaceutical Bulletin, vol. 34, no. 3, pp. 396–400, 2011.
[2] I. Arnaoutova and H. K. Kleinman, “In vitro angiogenesis:
endothelial cell tubeformation on gelled basement membrane
extract,” Nature Protocols, vol. 5, no. 4, pp. 628–635, 2010.
[ 3 ]Y .Z h a n g ,H .T a n g ,J .C a ie ta l . ,“ O v a r i a nc a n c e r - a s s o c i a t e d
ﬁbroblastscontributetoepithelialovariancarcinomametasta-
sis by promoting angiogenesis, lymphangiogenesis and tumor
cell invasion,” Cancer Letters, vol. 303, no. 1, pp. 47–55, 2011.
[4] P. Rouhi, S. L. C. Lee, Z. Cao, E. M. Hedlund, L. D. Jensen,
and Y. Cao, “Pathological angiogenesis facilitates tumor cell
dissemination and metastasis,” Cell Cycle,v o l .9 ,n o .5 ,p p .
913–917, 2010.
[5] A. Bruni-Cardoso, L. C. Johnson, R. L. Vessella, T. E. Pe-
terson, and C. C. Lynch, “Osteoclast-derived matrix met-
alloproteinase-9 directly aﬀects angiogenesis in the prostate
tumor-bone microenvironment,” Molecular Cancer Research,
vol. 8, no. 4, pp. 459–470, 2010.
[6] S. A. Schmid, A. Gaumann, M. Wondrak et al., “Lactate
adversely aﬀects the in vitro formation of endothelial cell
tubular structures through the action of TGF-β1,” Experimen-
t a lC e l lR e s e a r c h , vol. 313, no. 12, pp. 2531–2549, 2007.
[7] M. G. Alexandrakis, F. H. Passam, C. A. Pappa et al.,
“Serum evaluation of angiogenic cytokines basic ﬁbroblast
growth factor, hepatocyte growth factor and TNF-alpha in
patients with myelodysplastic syndromes: correlation with
bone marrow microvascular density,” International Journal of
Immunopathology and Pharmacology, vol. 18, no. 2, pp. 287–
295, 2005.
[8] B. H. Jiang and L. Z. Liu, “PI3K/PTEN signaling in angiogen-
esis and tumorigenesis,” Advances in Cancer Research, vol. 102,
pp. 19–65, 2009.
[9] N. Shafee, S. Kaluz, N. Ru, and E. J. Stanbridge, “PI3K/Akt
activity has variable cell-speciﬁc eﬀects on expression of HIF
target genes, CA9 and VEGF, in human cancer cell lines,”
Cancer Letters, vol. 282, no. 1, pp. 109–115, 2009.
[ 1 0 ]C .X i a ,Q .M e n g ,Z .C a o ,X .S h i ,a n dB .H .J i a n g ,“ R e g u l a t i o n
of aneiogenesis and tumor growth by p110 alpha and AKT1
via VEGF expression,” Journal of Cellular Physiology, vol. 209,
no. 1, pp. 56–66, 2006.
[11] K. D. Courtney, R. B. Corcoran, and J. A. Engelman, “The
PI3K pathway as drug target in human cancer,” Journal of
Clinical Oncology, vol. 28, no. 6, pp. 1075–1083, 2010.
[12] H. D. Skinner, J. Z. Zheng, J. Fang, F. Agani, and B. H. Jiang,
“Vascular endothelial growth factor transcriptional activation
is mediated by hypoxia-inducible factor 1α,H D M 2 ,a n d
p70S6K1 in response to phosphatidylinositol 3-kinase/AKT
signaling,” Journal of Biological Chemistry, vol. 279, no. 44, pp.
45643–45651, 2004.
[13] M. Graupera, J. Guillermet-Guibert, L. C. Foukas et al.,
“Angiogenesis selectively requires the p110α isoform of PI3K
to control endothelial cell migration,” Nature, vol. 453, no.
7195, pp. 662–666, 2008.
[ 1 4 ]J .D .S u ,L .D .M a y o ,D .B .D o n n e r ,a n dD .L .D u r d e n ,“ P T E N
and phosphatidylinositol 3 -kinase inhibitors up-regulate p53
and block tumor-induced angiogenesis: evidence for an eﬀect
onthetumorandendothelialcompartment,” CancerResearch,
vol. 63, no. 13, pp. 3585–3592, 2003.
[15] S. P. Staal, “Molecular cloning of the akt oncogene and its
human homologues AKT1 and AKT2: ampliﬁcation of AKT1
in a primary human gastric adenocarcinoma,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 84, no. 14, pp. 5034–5037, 1987.
[ 1 6 ]C .K r o n e r ,K .E y b r e c h t s ,a n dJ .W .N .A k k e r m a n ,“ D u a l
regulation of platelet protein kinase B,” Journal of Biological
Chemistry, vol. 275, no. 36, pp. 27790–27798, 2000.
[17] H. Tanaka, N. Fujita, and T. Tsuruo, “3-Phosphoinositide-
dependent protein kinase-1-mediated IκB kinase β(IKKB)
phosphorylation activates NF-κB signaling,” Journal of Biolog-
ical Chemistry, vol. 280, no. 49, pp. 40965–40973, 2005.
[18] B. H. Jiang, J. Z. Zheng, M. Aoki, and P. K. Vogt, “Phos-
phatidylinositol 3-kinase signaling mediates angiogenesis and
expression of vascular endothelial growth factor in endothelial
cells,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 97, no. 4, pp. 1749–1753, 2000.
[19] A. R. Tee, B. D. Manning, P. P. Roux, L. C. Cantley, and J.
Blenis, “Tuberous Sclerosis Complex gene products, Tuberin
andHamartin,controlmTORsignalingbyactingasaGTPase-
activatingproteincomplextowardRheb,”Current Biology,vol.
13, no. 15, pp. 1259–1268, 2003.
[20] P. R. Hagner, A. Schneider, and R. B. Gartenhaus, “Targeting
the translational machinery as a novel treatment strategy for
hematologic malignancies,” Blood, vol. 115, no. 11, pp. 2127–
2135, 2010.
[21] S. M. Planchon, K. A. Waite, and C. Eng, “The nuclear aﬀairs
of PTEN,” Journal of Cell Science, vol. 121, no. 3, pp. 249–253,
2008.
[22] M. Bonnet, M. Loosveld, B. Montpellier et al., “Posttran-
scriptional deregulation of MYC via PTEN constitutes a
major alternative pathway of MYC activation in T-cell acute
lymphoblastic leukemia,” Blood, vol. 117, no. 24, pp. 6650–
6659, 2011.
[23] L. R. Martins, P. L´ ucio, M. C. Silva et al., “Targeting CK2
overexpression and hyperactivation as a novel therapeutic tool
in chronic lymphocytic leukemia,” Blood, vol. 116, no. 15, pp.
2724–2731, 2010.
[24] A. Gutierrez, T. Sanda, R. Grebliunaite et al., “High frequency
of PTEN, PI3K, and AKT abnormalities in T-cell acute
lymphoblastic leukemia,” Blood, vol. 114, no. 3, pp. 647–650,
2009.
[25] L. S. Steelman, R. A. Franklin, S. L. Abrams et al., “Roles of the
Ras/Raf/MEK/ERK pathway in leukemia therapy,” Leukemia,
vol. 25, no. 7, pp. 1080–1094, 2011.6 Advances in Hematology
[26] I. Vivanco, N. Palaskas, C. Tran et al., “Identiﬁcation of the
JNK signaling pathway as a functional target of the tumor
suppressor PTEN,” Cancer Cell, vol. 11, no. 6, pp. 555–569,
2007.
[27] A. Suzuki, K. Hamada, T. Sasaki, T. W. Mak, and T. Nakano,
“RoleofPTEN/PI3Kpathwayinendothelialcells,”Biochemical
Society Transactions, vol. 35, no. 2, pp. 172–176, 2007.
[28] V. Baron, E. D. Adamson, A. Calogero, G. Ragona, and D.
Mercola, “The transcription factor Egr1 is a direct regulator
of multiple tumor suppressors including TGFβ1, PTEN, p53,
and ﬁbronectin,” Cancer Gene Therapy, vol. 13, no. 2, pp. 115–
124, 2006.
[29] K. B. Harikumar and B. B. Aggarwal, “Resveratrol: a multitar-
getedagentforage-associatedchronicdiseases,”Cell Cycle,vol.
7, no. 8, pp. 1020–1037, 2008.
[30] L. W. Xing, L. Zhang, K. Youker et al., “Free fatty acids
inhibit insulin signaling-stimulated endothelial nitric oxide
synthase activation through upregulating PTEN or inhibiting
Akt kinase,” Diabetes, vol. 55, no. 8, pp. 2301–2310, 2006.
[ 3 1 ]J .Y .C .C h o w ,M .B a n ,H .L .W ue ta l . ,“ T G F - β downregulates
PTEN via activation of NF-κB in pancreatic cancer cells,”
American Journal of Physiology, vol. 298, no. 2, pp. G275–
G282, 2010.
[32] L. Moore-Smith and B. Pasche, “TGFBR1 signaling and breast
cancer,”JournalofMammaryGlandBiologyandNeoplasia,vol.
16, no. 2, pp. 89–95, 2011.
[33] H. Yoshida, N. Okumura, Y. Kitagishi, Y. Nishimura, and S.
Matsuda, “Ethanol extract of Rosemary repressed PTEN
expression in K562 culture cells,” International Journal of
Applied Biology and Pharmaceutical Technology , vol. 2, pp.
316–322, 2011.
[34] M. G. Pezzolesi, P. Platzer, K. A. Waite, and C. Eng, “Diﬀer-
ential expression of PTEN-targeting microRNAs miR-19a and
miR-21 in cowden syndrome,” American Journal of Human
Genetics, vol. 82, no. 5, pp. 1141–1149, 2008.
[35] C. G´ omez-Raposo, M. Mendiola, J. Barriuso, E. Casado,
D. Hardisson, and A. Redondo, “Angiogenesis and ovarian
cancer,” Clinical & Translational Oncology, vol. 11, no. 9, pp.
564–571, 2009.
[36] L. Ellis, H. Hammers, and R. Pili, “Targeting tumor angiogen-
esis with histone deacetylase inhibitors,” Cancer Letters, vol.
280, no. 2, pp. 145–153, 2009.
[37] Q. Li, M. Michaud, S. Canosa, A. Kuo, and J. A. Madri, “GSK-
3β: a signaling pathway node modulating neural stem cell and
endothelial cell interactions,” Angiogenesis,v o l .1 4 ,n o .2 ,p p .
173–185, 2011.
[ 3 8 ]M .A .P a l l e r o ,C .A .E l z i e ,J .C h e n ,D .F .M o s h e r ,a n dJ .E .
Murphy-Ullrich, “Thrombospondin 1 binding to calreticulin-
LRP1 signals resistance to anoikis,” FASEB Journal, vol. 22, no.
11, pp. 3968–3979, 2008.
[39] J. Chen, P. R. Somanath, O. Razorenova et al., “Akt1 regulates
pathological angiogenesis, vascular maturation and perme-
ability in vivo,” Nature Medicine, vol. 11, no. 11, pp. 1188–
1196, 2005.
[40] M. Kafousi, T. Vrekoussis, E. Tsentelierou et al., “Immuno-
histochemical study of the angiogenetic network of VEGF,
HIF1α, VEGFR-2 and endothelial nitric oxide synthase
(eNOS) in human breast cancer,” Pathology and Oncology
Research, vol. 18, no. 1, pp. 33–41, 2012.
[41] Y. Lu, Y. Xiong, Y. Huo et al., “Grb-2-associated binder
1 (Gab1) regulates postnatal ischemic and VEGF-induced
angiogenesis through the protein kinase A-endothelial NOS
pathway,”ProceedingsoftheNationalAcademyofSciencesofthe
United States of America, vol. 108, no. 7, pp. 2957–2962, 2011.
[42] Q. J. Zhang, S. L. Mcmillin, J. M. Tanner, M. Palionyte, E.
D. Abel, and J. D. Symons, “Endothelial nitric oxide synthase
phosphorylation in treadmill-running mice: role of vascular
signalling kinases,” Journal of Physiology, vol. 587, no. 15, pp.
3911–3920, 2009.
[43] B. H. Jiang and L. Z. Liu, “AKT signaling in regulating an-
giogenesis,” Current Cancer Drug Targets, vol. 8, no. 1, pp. 19–
26, 2008.
[44] C. X. Bian, Z. Shi, Q. Meng, Y. Jiang, L. Z. Liu, and B. H.
Jiang, “P70S6K 1 regulation of angiogenesis through VEGF
and HIF-1α expression,” Biochemical and Biophysical Research
Communications, vol. 398, no. 3, pp. 395–399, 2010.
[45] D. Kong and T. Yamori, “Phosphatidylinositol 3-kinase
inhibitors: promising drug candidates for cancer therapy,”
Cancer Science, vol. 99, no. 9, pp. 1734–1740, 2008.
[46] K. Yu, J. Lucas, T. Zhu et al., “PWT-458, a novel pegylated-17-
hydroxywortmannin, inhibits phosphatidylinositol 3-kinase
signaling and suppresses growth of solid tumors,” Cancer
Biology and Therapy, vol. 4, no. 5, pp. 538–545, 2005.
[47] D. W. Kim, J. Huamani, A. Fu, and D. E. Hallahan, “Molecular
strategies targeting the host component of cancer to enhance
tumor response to radiation therapy,” International Journal of
Radiation Oncology Biology Physics, vol. 64, no. 1, pp. 38–46,
2006.
[48] H. R. Fei, G. Chen, J. M. Wang, and F. Z. Wang, “Perifosine
inducescellcyclearrestandapoptosisinhumanhepatocellular
carcinoma cell lines by blockade of Akt phosphorylation,”
Cytotechnology, vol. 62, no. 5, pp. 449–460, 2010.
[49] T. Maﬀucci, E. Piccolo, A. Cumashi et al., “Inhibition of
the phosphatidylinositol 3-kinase/Akt pathway by inositol
pentakisphosphate results in antiangiogenic and antitumor
eﬀects,” Cancer Research, vol. 65, no. 18, pp. 8339–8349, 2005.
[50] S. Romano, A. L. Di Pace, A. Sorrentino, R. Bisogni, L.
Sivero, and M. F. Romano, “FK506 binding proteins as
targets in anticancer therapy,” Anti-Cancer Agents in Medicinal
Chemistry, vol. 10, no. 9, pp. 651–656, 2010.
[51] C. Zhiyong, L. Wentong, Y. Xiaoyang, and P. Ling, “PTEN’s
regulation of VEGF and VEGFR1 expression and its clinical
signiﬁcance in myeloid leukemia,” Medical Oncology. In press.